

**Thank you for viewing this presentation.**

**We would like to remind you that this material is the property of the author. It is provided to you by the ERS for your personal use only, as submitted by the author.**

**© 2007 by the author**



European Respiratory  
Society

# **Pathology of preneoplasia and common lung cancers**

**Elisabeth Brambilla**

**INSERM U823 Department of Pathology  
CHU Grenoble France**

# **Lung Cancer Classification revised in 1999 (WHO)**

- 17 years elapsed since the 1981 WHO classification
- Progress in understanding genetic and molecular basis of carcinogenesis
- Foundation for tumor diagnosis and patient therapy
- Cornerstone of comparative studies: clinical, epidemiologic and biological
- Complemented with clinical and genetic features of entities : **Pathology and genetics (WHO 2004)**

# **Histological classification of lung tumors (WHO 1999 - 2004)**

**Squamous Cell Carcinoma**

**Small Cell Carcinoma**

**Adenocarcinoma**

**Large Cell Carcinoma**

**Adeno Squamous Carcinoma**

**Sarcomatoid carcinoma**

**Carcinoid tumors**

**Salivary gland tumors**


**Preinvasive lesions**

# Preinvasive lesions

- Squamous dysplasia
  - mild
  - moderate
  - severe
- Carcinoma in situ
- Atypical adenomatous hyperplasia (AAH)
- Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia




# Normal bronchial epithelium






# Bronchial epithelium: hyperplasia






# Squamous metaplasia






# Mild dysplasia






# Moderate dysplasia






# Severe dysplasia






# Carcinoma in situ






# Invasive carcinoma: T1




# Pre- and neoplastic bronchial lesions

Hyperplasia



Metaplasia



Dysplasia



In situ carcinoma



Invasive carcinoma


## Molecular Identity

- . Cell cycle regulation
- . Apoptosis / Senescence
- . Angiogenesis / Migration




# **Atypical Alveolar Hyperplasia (AAH)**

- **A preinvasive lesion for Bronchiolo Alveolar Carcinoma (BAC)**
- **Focal lesion ( 1-10 mm ) most often less than 3mm**
- **Slightly atypical epithelial cells covering alveoli and respiratory bronchioles**
- **Differential diagnosis with BAC**
  - **size  $\geq$  5mm**
  - **no gaps between cells**
  - **more severe atypia**










# **Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia**


- **A proliferation of neuroendocrine cells confined to the bronchiolar epithelium**
- **Scattered single cells, small nodules or linear proliferations**
- **Often associated with tumourlets**

# Neuroendocrine hyperplasia






# Neuroendocrine hyperplasia






# Tumourlet





**Tumourlet : less than 5mm    > 5mm : carcinoid**





# Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia

- **Idiopathic:** not a simple reaction to lung inflammation or fibrosis
- **A preneoplastic lesions:** some patients develop one or more carcinoid tumors
- A subset of patients have obstructive airway disease

# Squamous cell carcinoma

A malignant epithelial tumour showing keratinization and/or intercellular bridges

## Variants:

Papillary


Clear cell

Small cell

Basaloid




# Squamous cell carcinoma






# Squamous cell carcinoma






# Squamous cell carcinoma: papillary variant





# Squamous cell carcinoma: basaloid variant





# Small Cell Carcinoma

**WHO 1999-2004**

**Small Cell Carcinoma**

**Variant**


- **Combined Small Cell Carcinoma**

**WHO 1981**

**Small Cell Carcinoma**

**Oat cell**


**Intermediate  
Combined**


























# SCLC: NCAM






# SCLC: Chromogranin






# SCLC: TTF1





# SCLC combined





# WHO 1999 - 2004

## Adenocarcinoma

- . **Adenocarcinoma mixed subtype**
- . Acinar adenocarcinoma
- . Papillary adenocarcinoma
- . **Bronchioloalveolar carcinoma**
  - Non-mucinous
  - Mucinous
  - Mixed mucinous - non mucinous
- . Solid adenocarcinoma with mucin
- . Variants:

# WHO 1981

## Adenocarcinoma

- a. Acinar
- b. Papillary
- c. Bronchioloalveolar carcinoma
- d. Solid adenocarcinoma with mucus formation




# Adenocarcinoma

- 85% display mixed histology
  - **Adenocarcinoma mixed type**: more than one subtype
- **Bronchioloalveolar carcinoma**  
restrictive definition: a non invasive tumor




# Adenocarcinoma: acinar






# Adenocarcinoma: papillary






# Bronchioloalveolar carcinoma (BAC)





## BAC : Clara Cell Type





# **Bronchioloalveolar carcinoma (BAC)**

- **Pure “lepidic” growth pattern along respected alveolar walls**
  - **No invasion (stromal, vascular, pleural)**
  - **No central scar, no desmoplastic stromal reaction**
  - **No papillary structures in alveolar lumens**
- 
- ➔ **Most previously reported BAC are now adenocarcinoma mixed sub type**
  - ➔ **The diagnosis of BAC cannot be achieved on small biopsies**



# **Bronchioloalveolar carcinoma (non invasive)**

**Significant association with**

- pathological stage I**

**$p < 0,001$**

- absence of lymph node metastasis**

**$p < 0,001$**

- 5 years patient survival among stage I cases**

**$p < 0,005$**


**Noguchi M. (type AB-BAC < 2cm) Cancer 1995**

**Yokose et al Lung Cancer 2000**

**Suzuki et al Ann Thorac Surg 2002**




# BAC : mucinous type





# Mucinous BAC : satellite lesion






## 2cm Adenocarcinoma








**Central scar : Acinous adenocarcinoma**










**Periphery : BAC component**







# Bronchioloalveolar carcinoma: clinical significance

- **Less than 2 cm BAC can be curable by economic surgical resection:**

**100% - 5 year survival**

Noguchi et al Cancer 1995

- **Size of central scar** in ADC with peripheral

**BAC less than 3cm**


- **< 5mm**                      **100% 5 year survival**
- **5-15mm**                    **71% 5 year survival**
- **≥ 15mm**                   **40% 5 year survival**

**independent prognostic factor  $p = 0.01$**

Suzuki et al. Ann Thorac Surg 2000

Terasaki et al Am. J. Surg. Pathol. 2003







# WHO 1999

## 1.3.4. Large cell carcinoma

### Variants:

1.3.4.1. **Large cell neuroendocrine carcinoma**

**Combined large cell neuroendocrine carcinoma**


1.3.4.2. **Basaloid carcinoma**

1.3.4.3. **Lymphoepithelioma-like carcinoma**

1.3.4.4. **Clear cell carcinoma**


1.3.4.5. **Large cell carcinoma with rhabdoid phenotype**

# Large cell carcinoma: NOS






# Large Cell Neuroendocrine Carcinoma (LCNEC)





**NCAM**






# Large Cell NEuroendocrine Carcinoma (LCNEC)

- A variant of large cell carcinoma
- A high grade NE tumor
- Characteristic features
  - Neuroendocrine morphology (rosettes ...)
  - Non small cell cytology (  $\neq$  SCLC)
  - High mitotic rate  $\geq 11$  per  $2\text{mm}^2$   
( $\neq$  Atypical carcinoid)
- 15 - 20% of LCNEC are **Combined LCNEC**



# LCNEC combined



# **LCNEC: clinical features**

- **Heavy smokers. Mean age 62 years**
- **Poor prognosis: 27% - 5 y. survival  
9% - 10 y. survival**
- **Not significantly different from SCLC**
- **Surgical resection recommended**
- **Chemotherapy sensitivity?**

**SCLC chemotherapy type ?**

**Rossi et al JCO 2005**



# The spectrum of neuroendocrine (NE) proliferation and neoplasms

## I - NE cell hyperplasia and tumorlets

- A. NE cell hyperplasia

- B. Tumorlets

## II - Tumors with NE morphology

- A. Typical carcinoid

- B. Atypical carcinoid

- C. Large cell neuroendocrine carcinoma


- D. Small cell carcinoma

## III - Non small cell carcinomas with NE differentiation


# Lung neuroendocrine tumors

- Carcinoids: **Typical carcinoid**  
**Atypical carcinoid**
  - ➔ Sharp histopathological definition
  - ➔ Significant prognostic differences












# Carcinoids: Typical versus Atypical

	Mitoses	Necrosis	5y. survival	10y. survival
Typical carcinoid	< 2/ 2mm <sup>2</sup>	0	87%	87%
Atypical carcinoid	2-10/ 2mm <sup>2</sup>	+/-	56%	35%

W.D. Travis Am. J. Surg. Pathol. 1998

# PULMONARY NE TUMORS

## KAPLAN MEIER SURVIVAL ESTIMATION



AFIP/IASLC NE STUDY 8-97 (N=331; 78 TC, 81 AC, 78 LCNEC, 88 SCLC)




# Large cell carcinoma

- **Large cell carcinoma :**  
no clinical significance
- **Two variants with clinical significance**
  - **Large cell neuroendocrine carcinoma (5%)**
  - **Basaloid carcinoma (5%)**


# Basaloid carcinoma

- Proliferation of "reserve" stem cells
- No neuroendocrine markers
- High proliferative index
- Poor prognosis












# Survival of stage I BC vs NSCLC



**WHO 1999 - 2004**

## **Sarcomatoid carcinomas**

**Pleomorphic carcinoma**

**Spindle cell carcinoma**

**Giant cell carcinoma**


**Carcinosarcoma**

**Pulmonary blastoma**




# Sarcomatoid carcinoma

- Express the features of epithelial to mesenchymal transition
- Pleiomorphic carcinoma: 10% of giant or spindle cells
- Large peripheral tumors often invading chest and with endobronchial growth
- Differential diagnosis: sarcoma





Ker.



# **Pleomorphic Carcinoma (Sarcomatoid carcinoma)**

- **Poor prognosis**
  - **median survival: 19 months**
  - **47% - 5 year survival at stage I**

Rossi et al Am J. Surg Pathol 2003

➔ **Disease related survival significantly shorter than NSCLC stage I**



# **Immuno histochemistry**

## **Electron microscopy**



### **Differential diagnosis**

- **Large cell Neuroendocrine Carcinoma / Basaloid**
- **Carcinoma**
- **Adenocarcinoma / Mesothelioma (calretinin, CK5-6, ACE...)**
- **Adenocarcinoma / Primitive / Metastatic (TTF1)**
- **Pleiomorphic carcinoma / Sarcoma (Ck)**
- **Sarcoma (desmin, E.M.)**
- **Melanoma (HMB45, S100)**



World Health Organization Classification of Tumours



WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart

## Pathology & Genetics

### Tumours of the Lung, Pleura, Thymus and Heart

Edited by William D. Travis, Elizabeth Brambilla,  
Hans K. Muller-Hermelink & Curtis C. Harris

